Mabpharm Limited (HK:2181) has released an update.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Mabpharm Limited has received approval from the Drug Regulatory Authority of Pakistan for its core product, CMAB008, an infliximab biosimilar used to treat several conditions including ulcerative colitis, rheumatoid arthritis, and psoriasis. This development marks a significant milestone for the company, offering a more cost-effective treatment option for patients. Investors might find this approval promising as it potentially enhances Mabpharm’s market reach and product portfolio.
For further insights into HK:2181 stock, check out TipRanks’ Stock Analysis page.